Download Now: 7 Unstoppable Growth Engines of India's $10 Trillion Bull Run...
Here is the latest financial fact sheet of NATCO PHARMA. For more details, see the NATCO PHARMA quarterly results and NATCO PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.9 |
No. of shares | m | 179.11 |
1 Week | % | 3.7 |
1 Month | % | 7.6 |
1 Year | % | 81.0 |
52 week H/L | Rs | 1,107.9/564.2 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
NATCO PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 849 | 738 | 995 | 1,189 | 847 | |
Low | Rs | 557 | 450 | 492 | 750 | 502 | |
Sales per share (Unadj.) | Rs | 114.6 | 105.2 | 112.5 | 106.6 | 148.4 | |
Earnings per share (Unadj.) | Rs | 35.2 | 25.2 | 24.3 | 9.3 | 39.2 | |
Diluted earnings per share | Rs | 35.9 | 25.6 | 24.7 | 9.5 | 39.9 | |
Cash flow per share (Unadj.) | Rs | 39.6 | 30.6 | 30.7 | 17.1 | 48.2 | |
Dividends per share (Unadj.) | Rs | 6.25 | 6.75 | 5.25 | 4.50 | 5.50 | |
Adj. dividends per share | Rs | 6.38 | 6.86 | 5.34 | 4.59 | 5.60 | |
Avg Dividend yield | % | 0.9 | 1.1 | 0.7 | 0.5 | 0.8 | |
Book value per share (Unadj.) | Rs | 189.2 | 206.0 | 225.1 | 233.4 | 267.1 | |
Adj. book value per share | Rs | 193.1 | 209.4 | 229.1 | 237.9 | 272.1 | |
Shares outstanding (eoy) | m | 182.75 | 182.07 | 182.34 | 182.52 | 182.47 | |
Price / Sales ratio | x | 6.1 | 5.6 | 6.6 | 9.1 | 4.5 | |
Avg P/E ratio | x | 20.0 | 23.6 | 30.6 | 104.1 | 17.2 | |
P/CF ratio (eoy) | x | 17.8 | 19.4 | 24.2 | 56.6 | 14.0 | |
Price / Book Value ratio | x | 3.7 | 2.9 | 3.3 | 4.2 | 2.5 | |
Dividend payout | % | 17.8 | 26.8 | 21.6 | 48.3 | 14.0 | |
Avg Mkt Cap | Rs m | 128,471 | 108,130 | 135,564 | 176,990 | 123,049 | |
Total wages/salary | Rs m | 3,559 | 3,750 | 4,149 | 4,448 | 4,867 |
NATCO PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 20,945 | 19,150 | 20,521 | 19,448 | 27,071 | |
Other income | Rs m | 1,302 | 1,074 | 1,060 | 990 | 1,285 | |
Total revenues | Rs m | 22,247 | 20,224 | 21,581 | 20,438 | 28,356 | |
Gross profit | Rs m | 7,948 | 5,826 | 6,038 | 2,635 | 9,117 | |
Depreciation | Rs m | 810 | 998 | 1,169 | 1,426 | 1,638 | |
Interest | Rs m | 193 | 215 | 133 | 177 | 145 | |
Profit before tax | Rs m | 8,247 | 5,687 | 5,796 | 2,022 | 8,619 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,823 | 1,106 | 1,372 | 322 | 1,466 | |
Profit after tax | Rs m | 6,424 | 4,581 | 4,424 | 1,700 | 7,153 | |
Gross profit margin | % | 37.9 | 30.4 | 29.4 | 13.5 | 33.7 | |
Effective tax rate | % | 22.1 | 19.4 | 23.7 | 15.9 | 17.0 | |
Net profit margin | % | 30.7 | 23.9 | 21.6 | 8.7 | 26.4 |
NATCO PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 23,472 | 23,256 | 23,448 | 24,867 | 30,003 | |
Current liabilities | Rs m | 7,287 | 6,853 | 5,256 | 7,104 | 6,831 | |
Net working cap to sales | % | 77.3 | 85.7 | 88.7 | 91.3 | 85.6 | |
Current ratio | x | 3.2 | 3.4 | 4.5 | 3.5 | 4.4 | |
Inventory Days | Days | 42 | 36 | 63 | 72 | 63 | |
Debtors Days | Days | 88 | 105 | 73 | 116 | 115 | |
Net fixed assets | Rs m | 19,559 | 22,622 | 24,471 | 26,224 | 26,571 | |
Share capital | Rs m | 365 | 364 | 365 | 365 | 365 | |
"Free" reserves | Rs m | 34,217 | 37,136 | 40,676 | 42,237 | 48,373 | |
Net worth | Rs m | 34,582 | 37,500 | 41,041 | 42,602 | 48,738 | |
Long term debt | Rs m | 0 | 9 | 0 | 0 | 0 | |
Total assets | Rs m | 43,031 | 45,878 | 47,919 | 51,091 | 56,574 | |
Interest coverage | x | 43.7 | 27.5 | 44.6 | 12.4 | 60.4 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | |
Return on assets | % | 15.4 | 10.5 | 9.5 | 3.7 | 12.9 | |
Return on equity | % | 18.6 | 12.2 | 10.8 | 4.0 | 14.7 | |
Return on capital | % | 24.4 | 15.7 | 14.4 | 5.2 | 18.0 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 14.0 | 9.5 | 10.9 | 20.0 | 10.2 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 2,939 | 1,818 | 2,231 | 3,882 | 2,772 | |
Fx inflow | Rs m | 11,536 | 8,736 | 11,194 | 8,881 | 17,256 | |
Fx outflow | Rs m | 2,939 | 1,818 | 2,231 | 3,882 | 2,772 | |
Net fx | Rs m | 8,597 | 6,918 | 8,963 | 4,999 | 14,484 |
NATCO PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 6,688 | 4,173 | 2,988 | 465 | 8,491 | |
From Investments | Rs m | -6,122 | -1,670 | -1,033 | -53 | -4,771 | |
From Financial Activity | Rs m | -509 | -2,508 | -1,857 | 348 | -3,630 | |
Net Cashflow | Rs m | 66 | -85 | 60 | 853 | 208 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: G S Murthy | COMP SEC: Chekuri Venkat Ramesh | YEAR OF INC: 1981 | BSE CODE: 524816 | FV (Rs): 2 | DIV YIELD (%): 0.5 |
Read: NATCO PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare NATCO PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.